The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials
Open accessAbstract
Background: Neuropathy is a debilitating toxicity associated with various chemotherapy agents. We evaluated the association between common comorbid conditions and the development of peripheral neuropathy in patients treated with taxane-based chemotherapy. Methods: We examined the Southwest Oncology Group database to identify phase II and III trials that included taxane therapy from 1999 to 2011. We linked the Southwest Oncology Group clinical records to Medicare claims data according to Social Security number, sex, and date of birth. The following disease conditions potentially associated with peripheral neuropathy were evaluated: diabetes, hypothyroidism, hypercholesterolemia, hypertension, varicella zoster, peripheral vascular disease, and autoimmune diseases. Multivariate logistic regression was used to model the odds of experiencing grade 2 to 4 neuropathy. Results: A total of 1,401 patients from 23 studies were included in the analysis. Patients receiving paclitaxel were more likely to experience grade 2 to 4 neuropathy compared with docetaxel (25% v 12%, respectively; OR, 2.20; 95% CI, 1.52 to 3.18; P < .001). The inclusion of a platinum agent was also associated with greater neuropathy (OR, 1.68; 95% CI, 1.18 to 2.40; P = .004). For each increase in age of 1 year, the odds of neuropathy increased 4% (P = .006). Patients with complications from diabetes had more than twice the odds of having neuropathy (OR, 2.13; 95% CI, 1.31 to 3.46; P = .002) compared with patients with no diabetes. In contrast, patients with autoimmune disease were half as likely to experience neuropathy (OR, 0.49; 95% CI, 0.24 to 1.02; P = .06). The other conditions were not associated with neuropathy. Conclusion: We found that in addition to drug-related factors, age and history of diabetes were independent predictors of the development of chemotherapy-induced peripheral neuropathy. Interestingly, we also observed that a history of autoimmune disease was associated with reduced odds of neuropathy. Patients with diabetic complications may choose to avoid paclitaxel or taxane plus platinum combination therapies if other efficacious options exist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy
Smith, G. L., Smith, B. D., Buchholz, T. A., Giordano, S. H., Garden, A. S., Woodward, W. A., Krumholz, H. M., Weber, R. S., Ang, K.-K., & Rosenthal, D. I. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6546 · Cited by 231
Research works printed but not linked: 22
- 10.1007/s10549-010-1278-0 · DOI · Paper page
- 10.1200/JCO.2005.04.0543 · DOI · Paper page
- 10.1007/978-3-319-16366-6_6 · DOI
- 10.1200/JCO.2013.54.0914 · DOI · Paper page
- 10.1200/JCO.1993.11.10.2010 · DOI · Paper page
- Rowinsky EK, 1993, Semin Oncol, 20, 1
- 10.1158/1078-0432.CCR-15-0586 · DOI
- 10.1200/JCO.2011.39.8446 · DOI
- 10.1006/gyno.1996.0090 · DOI
- 10.6004/jnccn.2015.0057 · doi:10.6004/jnccn.2015.0057
- 10.1038/ncpneuro0504 · DOI · Paper page
- 10.1056/NEJM199507133330203 · DOI · Paper page
- Kanbayashi Y, 2013, Anticancer Res, 33, 1153
- 10.1007/s10549-011-1671-3 · DOI
- 10.1177/1077558707305409 · DOI · Paper page
- 10.1055/s-0034-1390391 · DOI
- 10.1007/s00415-014-7354-3 · doi:10.1007/s00415-014-7354-3
- 10.1016/j.jneuroim.2014.01.012 · doi:10.1016/j.jneuroim.2014.01.012
- 10.1016/j.cyto.2012.03.027 · DOI · Paper page
- 10.1213/ANE.0b013e31824b0191 · DOI
- 10.1002/cncr.21999 · DOI
- 10.1093/jnci/djj305 · DOI · Paper page
Cited by
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.-M., Cristea, M., DeRosa, M., Eisenhauer, E. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0007 · Cited by 715
Nekhlyudov, L., Mollica, M. A., Jacobsen, P. B., Mayer, D. K., Shulman, L. N., & Geiger, A. M. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz089 · Cited by 416
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022: Featured Updates to the NCCN Guidelines
Armstrong, D. K., Alvarez, R. D., Backes, F. J., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.-M., Chitiyo, V. C., Cristea, M., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0047 · Cited by 401
Soto-Perez-de-Celis, E., Li, D., Yuan, Y., Lau, Y. M., & Hurria, A. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30348-6 · Cited by 400
Metadata
- Authors
- Hershman, D. L., Till, C., Wright, J. D., Awad, D., Ramsey, S. D., Barlow, W. E., Minasian, L. M., & Unger, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-09-01
- Volume
- 34
- Issue
- 25
- Pages
- 3014-3022
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2471488931
- Cited by
- 246
- References
- 1
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. https://app.cochat.ai/papers/10.1200/jco.2015.66.2346
- The paper
- Hershman, D. L., Till, C., Wright, J. D., Awad, D., Ramsey, S. D., Barlow, W. E., Minasian, L. M., & Unger, J. (2016). Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.66.2346
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.